JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Microbot Medical Inc

Fechado

2.09 2.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.03

Máximo

2.1

Indicadores-chave

By Trading Economics

Rendimento

113K

-3.5M

Funcionários

43

EBITDA

-561K

-4.1M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+267.65% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-24M

146M

Abertura anterior

-0.36

Fecho anterior

2.09

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Microbot Medical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 23:08 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 23:07 UTC

Ganhos

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:20 UTC

Ganhos

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 de abr. de 2026, 23:27 UTC

Conversa de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 de abr. de 2026, 23:22 UTC

Ganhos

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 de abr. de 2026, 22:52 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:33 UTC

Ganhos

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 de abr. de 2026, 22:05 UTC

Ganhos

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 21:57 UTC

Ganhos

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 de abr. de 2026, 21:55 UTC

Ganhos

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 de abr. de 2026, 21:53 UTC

Ganhos

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparação entre Pares

Variação de preço

Microbot Medical Inc Previsão

Preço-alvo

By TipRanks

267.65% parte superior

Previsão para 12 meses

Média 7.5 USD  267.65%

Máximo 12 USD

Mínimo 5 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Microbot Medical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.52 / 2.57Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat